ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2025
Comparative Study on the Neuroprotective Effects of Perindopril and Benazepril in Experimentally-induced Chronic Mild Stress in Rats.
Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost effective industrial scale synthesis of bromo-benzo[b]azepinone: an intermediate for benazepril.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression remains a major global health issue, characterized by inadequate response rates to conventional antidepressant therapies. This highlights a critical need for novel treatment strategies. Our study investigated the antidepressant effects of benazepril, a non-centrally acting angiotensin-converting enzyme (ACE) inhibitor, and compared it with perindopril, a centrally acting ACE inhibitor. We utilized a rat model of depression induced by chronic unpredictable mild stress (CUMS) to evaluate their efficacy. The CUMS protocol effectively caused several depression-like behaviors and impaired neurobehavioral functions in the rats. Analysis of brain tissues from these animals revealed several key pathological hallmarks: diminished monoamine neurotransmitter levels, heightened oxidative stress, robust inflammatory responses, and increased apoptotic processes. Our findings demonstrated that both perindopril and benazepril significantly reversed these CUMS-induced deficits. Specifically, both ACE inhibitors exhibited potent antioxidant, anti-inflammatory, and anti-apoptotic properties. This was coupled with their effective inhibition of the renin-angiotensin-aldosterone system (RAAS) signaling pathway, a mechanism known to be implicated in stress responses and mood disorders. Notably, while many ACE inhibitors have been extensively studied for their central effects, research on benazepril's direct effects within the brain or central nervous system in rats is notably limited. This study is among the first to highlight the antidepressant potential of benazepril, a non-centrally acting ACE inhibitor, and provides novel insights into its comparative efficacy against perindopril. These results collectively emphasize the broader therapeutic potential of ACE inhibitors in treating depression and underscore the need for further research to fully explore their underlying mechanisms and diverse applications in psychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.